B+
Bull case
25%
Probability
Target price
$4.40
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
GDRX
GoodRxBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The raised 2026 outlook, strong Q2 Pharma Direct and subscription growth, and $80.8 million of Q2 operating cash flow support a path back to growth if newer businesses continue to scale. [#SEC-8K-2026-08-05]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
A reported August Form 4 records sales by Francisco Partners IV; insider activity is not evidence of operating performance. [#SEC-FORM4-2026-08-26]
Momentum
70
Value
69
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.70 · Bull $4.40 · Bear $2.60Analysis 2026-10-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $3.95
Why
Momentum70 · Δ7d +0.6
Value69 · Δ7d -0.2
Sentiment49 · Δ7d -4.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • A reported August Form 4 records sales by Francisco Partners IV; insider activity is not evidence of operating performance. [#SEC-FORM4-2026-08-26]
- • GoodRx reported $492.5 million of outstanding debt and $296.1 million of cash at June 30, 2026. [#SEC-8K-2026-08-05]
- • Prescription transactions still represented $106.4 million of Q2 revenue and declined 26% year over year; adjusted EBITDA also fell from $69.4 million to $63.7 million.
Catalyst clock
2026-12-31
Raised 2026 outlook remains a test
Lead driver: Value · See fundamentals
Momentum
70
8% active weight
Current posture
7d trendImproving
Δ7d
+0.6
Δ21d
-1.4
Value
69
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.6
Sentiment
49
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
-14.8
Why this grade
Composite grade B. Momentum 70.0 / Value 69.0 / Sentiment 49.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-11. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.70
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.21B
Beta
1.50
Shares Out
341.15M
P/E (TTM)
33.0
P/S (TTM)
1.20
P/FCF (TTM)
9.16
Rev YoY
-1.3%
EPS YoY
-31.9%
Gross Margin
+79.5%
Op Margin
+12.0%
Net Debt
$280.99M
Current Ratio
1.38
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data